|
Name |
Talarolutin C
|
Molecular Formula | C21H28O6 | |
IUPAC Name* |
(1R,2R,4S,6S,8R,11R,15R)-8-hydroxy-2,7,7,11,15-pentamethyl-5,12,14-trioxapentacyclo[9.8.0.02,8.04,6.013,18]nonadec-13(18)-ene-3,17-dione
|
|
SMILES |
C[C@@H]1CC(=O)C2=C(O1)O[C@@]3(CC[C@@]4([C@@]([C@H]3C2)(C(=O)[C@@H]5[C@H](C4(C)C)O5)C)O)C
|
|
InChI |
InChI=1S/C21H28O6/c1-10-8-12(22)11-9-13-19(4,27-17(11)25-10)6-7-21(24)18(2,3)16-14(26-16)15(23)20(13,21)5/h10,13-14,16,24H,6-9H2,1-5H3/t10-,13+,14-,16-,19-,20+,21-/m1/s1
|
|
InChIKey |
UHRCUSBDMVNETF-FHFLJEKDSA-N
|
|
Synonyms |
alarolutin C; Talarolutin C; J3.580.496J
|
|
CAS | NA | |
PubChem CID | 132529127 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 376.4 | ALogp: | 1.7 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 85.4 | Aromatic Rings: | 5 |
Heavy Atoms: | 27 | QED Weighted: | 0.654 |
Caco-2 Permeability: | -4.805 | MDCK Permeability: | 0.00002970 |
Pgp-inhibitor: | 0.017 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.893 |
Blood-Brain-Barrier Penetration (BBB): | 0.797 | Plasma Protein Binding (PPB): | 68.00% |
Volume Distribution (VD): | 0.811 | Fu: | 39.81% |
CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.181 |
CYP2C19-inhibitor: | 0.06 | CYP2C19-substrate: | 0.519 |
CYP2C9-inhibitor: | 0.076 | CYP2C9-substrate: | 0.018 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.038 |
CYP3A4-inhibitor: | 0.372 | CYP3A4-substrate: | 0.654 |
Clearance (CL): | 6.569 | Half-life (T1/2): | 0.415 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.206 |
Drug-inuced Liver Injury (DILI): | 0.785 | AMES Toxicity: | 0.018 |
Rat Oral Acute Toxicity: | 0.949 | Maximum Recommended Daily Dose: | 0.899 |
Skin Sensitization: | 0.395 | Carcinogencity: | 0.924 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.015 |
Respiratory Toxicity: | 0.936 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003409 | 0.682 | D0G6AB | 0.250 | ||||
ENC003406 | 0.571 | D0W2EK | 0.246 | ||||
ENC003407 | 0.521 | D0Q6NZ | 0.241 | ||||
ENC003231 | 0.383 | D0U3GL | 0.241 | ||||
ENC002037 | 0.323 | D0I2SD | 0.237 | ||||
ENC002886 | 0.320 | D0Q4SD | 0.236 | ||||
ENC004409 | 0.320 | D0G8BV | 0.234 | ||||
ENC002749 | 0.304 | D0K7LU | 0.232 | ||||
ENC002750 | 0.304 | D0P0HT | 0.229 | ||||
ENC003843 | 0.301 | D06IIB | 0.227 |